Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Explore this paper's citation graph
Summary
It would appear that the future of angiogenic inhibitors lies in the intelligent combination of multiple targeted agents with other angiogenesis inhibitors, as well as more conventional therapies to maximise therapeutic effect.
- Type
- article
- Published
- 2011-08-01
- Cited by
- 40
- References
- 129
- Access
- Open access
- OpenAlex
- https://openalex.org/W21435792
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2699699
Keywords
Business, Investment (military), Natural resource economics, Industrial organization, Environmental resource management
References
- Can tumor angiogenesis be inhibited without resistance?
- Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
- Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
- Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.
- Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
- Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes
- The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
- SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
- Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
- The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model
- Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.
- P3-138: A Phase I open label study of continuous oral treatment with BIBF 1120 together with carboplatin and paclitaxel treated patients with non–small cell lung cancer (NSCLC)
- Sorafenib in advanced hepatocellular carcinoma.
- 1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
- Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
- VEGF-Trap: A VEGF blocker with potent antitumor effects
- Epidermal growth factor receptor in tumor angiogenesis.
- Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
- The biology of vascular endothelial growth factor.
Cited by
- Eupolyphaga sinensis Walker demonstrates angiogenic activity and inhibits A549 cell growth by targeting the KDR signaling pathway.
- Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial β1 integrin recycling
- Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.
- Enzymatic preparation of κ-carrageenan oligosaccharides and their anti-angiogenic activity.
- Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.
- A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis.
- Role of Integrins in Regulating Proteases to Mediate Extracellular Matrix Remodeling
- Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930.
- Vasohibin-1 Expression Is Regulated by Transforming Growth Factor-β/Bone Morphogenic Protein Signaling Pathway Between Tumor-Associated Macrophages and Pancreatic Cancer Cells
- In Vivo Monitoring of Angiogenesis Inhibition via Down-Regulation of Mir-21 in a VEGFR2-Luc Murine Breast Cancer Model Using Bioluminescent Imaging
- Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells
- The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth
- Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems.
- Imaging Key Biomarkers of Tumor Angiogenesis
- The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.
- Angiogenesis Inhibition by Bee Venom in Rat Aortic Model
- Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy
- Pathological functions of the small GTPase Arf6 in cancer progression: Tumor angiogenesis and metastasis
- Growth factor expression in normal and wounded skin: an investigation of scar-free wound healing in the leopard gecko (Eublepharis macularius)
- Combination treatment including targeted therapy for advanced hepatocellular carcinoma